Ivermectin, a powerful antiparasitic medication, has garnered significant attention in recent years for its efficacy in treating various parasitic infections. Originally developed for veterinary use, this versatile drug has since become a crucial tool in human medicine. In this comprehensive guide, we'll explore the range of parasites that ivermectin tablets can effectively eliminate, shedding light on its FDA-approved uses and geographic-specific applications.
1.General Specification(in stock)
(1)Injection
N/A
(2)Tablet
360mg/Tablet,Package:100 tablets/Bottle;80 bottles/Box
(3)API(Pure powder)
PE/Al foil bag/ paper box for Pure powder
HPLC≥99.0%
(4)Pill press machine
https://www.achievechem.com/pill-press
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-002
Ivermectin stromectol tablet CAS 70288-86-7
Analysis: HPLC, LC-MS, HNMR
Technology support: R&D Dept.-4
We provide ivermectin tablets, please refer to the following website for detailed specifications and product information.
Product: https://www.bloomtechz.com/oem-odm/tablet/ivermectin-stromectol-tablet.html
FDA-approved parasitic targets: Roundworms, lice, and scabies mites
The U.S. Food and Drug Administration (FDA) has approved ivermectin for treating several specific parasitic infections in humans. These FDA-approved uses include:
Roundworms (Strongyloidiasis)
Strongyloidiasis is an intestinal infection caused by the parasitic roundworm Strongyloides stercoralis. This soil-transmitted helminth can cause a range of symptoms, from mild gastrointestinal discomfort to severe, life-threatening complications in immunocompromised individuals. Ivermectin tablets(https://en.wikipedia.org/wiki/Ivermectin), the brand name for ivermectin, have shown remarkable efficacy in eradicating these parasites.
Head lice (Pediculus humanus capitis)
Head lice infestations are a common problem, particularly among school-aged children. Ivermectin has emerged as an effective treatment option for these pesky parasites. When used as directed, ivermectin can eliminate head lice and their eggs, providing relief from the intense itching and social stigma associated with these infestations.
Scabies mites (Sarcoptes scabiei)
Scabies, a highly contagious skin condition caused by tiny mites, can be effectively treated with ivermectin. The medication works by paralyzing and killing the mites, as well as their eggs. This helps to break the cycle of infestation and provides relief from the intense itching and discomfort associated with scabies.
While these are the primary FDA-approved uses for ivermectin in humans, the medication has shown promise in treating other parasitic infections as well. However, it's crucial to note that off-label use should only be considered under the guidance of a healthcare professional.
Why ivermectin powder is ineffective for certain parasitic infections
Despite its broad-spectrum antiparasitic activity, ivermectin tablets and other formulations may not be effective against all types of parasites. There are several reasons why ivermectin might be ineffective for certain parasitic infections:
Mechanism of action limitations
Ivermectin primarily works by binding to glutamate-gated chloride channels in invertebrate nerve and muscle cells. This mechanism is particularly effective against certain types of parasites, such as nematodes and arthropods. However, it may not be as effective against other types of parasites, such as protozoa or trematodes, which have different cellular structures and mechanisms.
Parasite resistance
As with many antiparasitic medications, there is a risk of parasites developing resistance to ivermectin over time. This can occur due to genetic mutations in the parasites or through selective pressure from repeated exposure to the drug. In some cases, parasites may evolve to become less susceptible to the effects of ivermectin, reducing its efficacy.
Inadequate drug concentrations
For ivermectin to be effective, it must reach therapeutic concentrations at the site of infection. In some cases, particularly with certain tissue-dwelling parasites, it may be challenging to achieve adequate drug levels in the affected areas. This can result in reduced efficacy or treatment failure.
Host factors
Individual variations in drug metabolism, immune system function, and other host factors can influence the effectiveness of ivermectin. Some patients may not respond as well to the medication due to these individual differences.
Lifecycle stage of the parasite
Ivermectin may be more effective against certain stages of a parasite's lifecycle than others. For example, it may be highly effective against adult worms but less so against larval stages or eggs. This can necessitate multiple treatments or combination therapies to achieve complete eradication.
Understanding these limitations is crucial for healthcare providers when considering ivermectin as a treatment option. In many cases, alternative antiparasitic medications or combination therapies may be necessary to effectively combat certain parasitic infections.
Geographic-specific parasites treatable with ivermectin tablets
The efficacy of ivermectin tablets extends beyond the FDA-approved uses, particularly in regions where certain parasitic infections are endemic. Here are some geographic-specific parasites that can be effectively treated with ivermectin:
River blindness (Onchocerciasis)
Prevalent in parts of Africa, Latin America, and Yemen, river blindness is caused by the parasitic worm Onchocerca volvulus. Ivermectin has been instrumental in mass drug administration programs aimed at eliminating this debilitating disease. The medication kills the microfilariae produced by adult worms, preventing the severe skin and eye complications associated with the infection.
Lymphatic filariasis
Also known as elephantiasis, this parasitic infection is caused by thread-like worms that inhabit the lymphatic system. Stromectol 3mg tablets, often used in combination with other medications, has proven effective in treating lymphatic filariasis in endemic regions of Africa, Asia, and the Western Pacific.
Gnathostomiasis
This parasitic infection, caused by the roundworm Gnathostoma spinigerum, is prevalent in Southeast Asia and parts of Central and South America. While not FDA-approved for this specific use, ivermectin has shown promise in treating gnathostomiasis, particularly in cases where traditional treatments have failed.
Cutaneous larva migrans
This skin condition, caused by the larvae of various hookworm species, is common in tropical and subtropical regions. Ivermectin has demonstrated efficacy in treating cutaneous larva migrans, providing a valuable alternative to topical treatments.
Mansonelliasis
Caused by filarial nematodes of the genus Mansonella, this parasitic infection is found in parts of Africa and South America. While not a first-line treatment, ivermectin has shown some efficacy in reducing microfilarial loads in infected individuals.
Ascariasis
Although not the primary treatment for this common roundworm infection, ivermectin has demonstrated effectiveness against Ascaris lumbricoides, particularly in mass drug administration programs in endemic areas.
It's important to note that while ivermectin has shown promise in treating these geographic-specific parasites, its use may not be approved by regulatory agencies in all countries. Healthcare providers in endemic regions often rely on local guidelines and clinical experience when prescribing ivermectin for these conditions.
Loiasis
Also known as African eye worm, loiasis is caused by the parasitic worm Loa loa and is endemic to certain parts of West and Central Africa. While ivermectin can be effective against loiasis, caution is required as rapid killing of microfilariae in heavily infected individuals can lead to severe adverse reactions.
Trichuriasis
Caused by the whipworm Trichuris trichiura, this soil-transmitted helminth infection is widespread in tropical and subtropical regions. Ivermectin, particularly when used in combination with other anthelmintic drugs, has shown promise in treating trichuriasis in mass drug administration programs.
Strongyloidiasis in immunocompromised patients
While strongyloidiasis is an FDA-approved indication for ivermectin, it's worth noting its particular importance in treating immunocompromised patients in endemic areas. These individuals are at risk of developing hyperinfection syndrome, a potentially fatal complication of strongyloidiasis.
Considerations for geographic-specific use
When considering the use of ivermectin for geographic-specific parasites, several factors must be taken into account:
Local prevalence and epidemiology of parasitic infections
Potential drug interactions with other medications commonly used in the region
Availability of alternative antiparasitic treatments
Local regulatory approvals and guidelines
Potential for development of drug resistance
Cost-effectiveness and feasibility of mass drug administration programs
Healthcare providers and public health officials in endemic regions must carefully weigh these factors when implementing ivermectin-based treatment strategies. Collaboration between local health authorities, international organizations, and research institutions is crucial for optimizing the use of ivermectin in combating geographic-specific parasitic infections.
Emerging research and future applications
As research into ivermectin's antiparasitic properties continues, new potential applications are being explored. Some areas of ongoing investigation include:
Efficacy against other neglected tropical diseases
Combination therapies to enhance antiparasitic effects and combat drug resistance
Novel formulations to improve bioavailability and reduce side effects
Potential applications in vector control strategies
These research efforts hold promise for expanding the role of ivermectin in global health, particularly in regions disproportionately affected by parasitic diseases.
Conclusion
Ivermectin tablets's versatility in treating a wide range of parasitic infections has made it an invaluable tool in global health efforts. From its FDA-approved uses against roundworms, lice, and scabies mites to its applications in combating geographic-specific parasites, ivermectin continues to play a crucial role in improving the lives of millions worldwide.
As we've explored, the effectiveness of stromectol tablets can vary depending on the specific parasite, host factors, and geographic considerations. Healthcare providers must carefully consider these factors when prescribing ivermectin, ensuring its appropriate use and maximizing its therapeutic potential.
For pharmaceutical companies, research institutions, and healthcare organizations seeking high-quality ivermectin and other antiparasitic medications, Shaanxi BLOOM TECH Co., Ltd. stands as a leading provider. With our state-of-the-art GMP-certified production facilities and expertise in advanced chemical reactions and purification techniques, we are well-equipped to meet the growing demand for these vital medications.
If you're involved in the pharmaceutical industry, polymer and plastics industry, paints and coatings industry, water treatment industry, oil and gas industry, or specialty chemicals industry, and are looking for a reliable partner for your chemical needs, we invite you to reach out to us. Our team is committed to providing top-quality products and tailored solutions to meet your specific requirements.
To learn more about our ivermectin products and other chemical offerings, please contact us at Sales@bloomtechz.com. Let's work together to advance global health and combat parasitic diseases.
References
Crump A, Ōmura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(2):13-28.
Gonzalez Canga A, Sahagún Prieto AM, Diez Liébana MJ, et al. The pharmacokinetics and interactions of ivermectin in humans--a mini-review. AAPS J. 2008;10(1):42-46.
Kircik LH, Del Rosso JQ, Layton AM, Schauber J. Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications. J Drugs Dermatol. 2016;15(3):325-332.
World Health Organization. Onchocerciasis: Key Facts. Geneva: World Health Organization; 2021.